Measuring Patient Quality of Life Following Treatment for Alopecia

References

• Papa CM. Hair. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. Boston: Butterworths; 1990:532–535.
   Google Scholar
• Rusticus S. Body image. In: Michalos AC, editor. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer Netherlands; 2014:420–423.
   Google Scholar
• Kwan S. Beauty. In: Michalos AC, editor. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer Netherlands; 2014:335–337.
   Google Scholar
• Chanprapaph K, Sutharaphan T, Suchonwanit P. Scalp biophysical characteristics in males with androgenetic alopecia: a comparative study with healthy controls. Clin Interv Aging. 2021;16:781–787. doi:10.2147/CIA.S310178
   PubMed Web of Science ®Google Scholar
• Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2017;11:7–12. doi:10.2147/CCID.S153768
   Web of Science ®Google Scholar
• Meephansan J, Thummakriengkrai J, Ponnikorn S, Yingmema W, Deenonpoe R, Suchonwanit P. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Arch Dermatol Res. 2017;309(9):729–738. doi:10.1007/s00403-017-1777-5
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–153. doi:10.1007/s40257-018-0387-0
   PubMed Web of Science ®Google Scholar
• Chanasumon N, Sriphojanart T, Suchonwanit P. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365–372. doi:10.2147/DDDT.S156467
   PubMed Web of Science ®Google Scholar
• Chanprapaph K, Udompanich S, Visessiri Y, Ngamjanyaporn P, Suchonwanit P. Nonscarring alopecia in systemic lupus erythematosus: a cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses. J Am Acad Dermatol. 2019;81(6):1319–1329. doi:10.1016/j.jaad.2019.05.053
   PubMed Web of Science ®Google Scholar
• Harnchoowong S, Suchonwanit P. PPAR-γ agonists and their role in primary cicatricial alopecia. PPAR Res. 2017;2017:2501248. doi:10.1155/2017/2501248
   Web of Science ®Google Scholar
• Sriphojanart T, Khunkhet S, Suchonwanit P. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. Dermatol Reports. 2017;9(2):7399. doi:10.4081/dr.2017.7399
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Hector CE, Bin Saif GA, McMichael AJ. Factors affecting the severity of central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55(6):e338–343. doi:10.1111/ijd.13061
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Chalermroj N, Khunkhet S. Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. Lasers Med Sci. 2019;34(6):1107–1114. doi:10.1007/s10103-018-02699-9
   PubMed Web of Science ®Google Scholar
• Alirezaei P, Ahmadpanah M, Rezanejad A, Soltanian A, Sadeghi Bahmani D, Brand S. Compared to controls, individuals with lichen planopilaris have more depression, a lower self-esteem, and a lower quality of life. Neuropsychobiology. 2019;78(2):95–103. doi:10.1159/000499135
   Web of Science ®Google Scholar
• Titeca G, Goudetsidis L, Francq B, et al. ‘The psychosocial burden of alopecia areata and androgenetica’: a cross-sectional multicentre study among dermatological out-patients in 13 European countries. J Eur Acad Dermatol Venereol. 2020;34(2):406–411. doi:10.1111/jdv.15927
   Web of Science ®Google Scholar
• Whoqol Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–1409. doi:10.1016/0277-9536(95)00112-K
   PubMed Web of Science ®Google Scholar
• The economist intelligence unit’s quality-of-life index. 2005. Available from: https://www.economist.com/media/pdf/quality_of_life.pdf. Accessed May 24, 2021.
   Google Scholar
• Veenhoven R. Quality of life (QOL), an overview. In: Michalos AC, editor. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer Netherlands; 2014:5265–5269.
   Google Scholar
• Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593–603. doi:10.1016/0021-9681(87)90019-1
   PubMedGoogle Scholar
• Committee for medicinal products for human use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London: European Medicines Agency; 2005.
   Google Scholar
• U.S. Food & Drug Administration. Clinical outcome assessment (COA): frequently asked questions. Available from: https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions. Accessed May 24, 2021.
   Google Scholar
• Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56(1):52–60. doi:10.1016/S0895-4356(02)00537-1
   PubMed Web of Science ®Google Scholar
• Kini SP, DeLong LK. Overview of health status quality-of-life measures. Dermatol Clin. 2012;30(2):209–221, xiii. doi:10.1016/j.det.2011.11.007
   Web of Science ®Google Scholar
• Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–164. doi:10.1136/bmj.305.6846.160
   PubMed Web of Science ®Google Scholar
• Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65(12):1304–1310. doi:10.2105/AJPH.65.12.1304
   PubMed Web of Science ®Google Scholar
• Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham health profile: subjective health status and medical consultations. Soc Sci Med A. 1981;15(3 Pt 1):221–229. doi:10.1016/0271-7123(81)90005-5
   PubMedGoogle Scholar
• Frisch MB, Cornell J, Villanueva M, Retzlaff PJ. Clinical validation of the quality of life inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 1992;4:92–101. doi:10.1037/1040-3590.4.1.92
   Google Scholar
• Hawthorne G, Richardson J, Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209–224. doi:10.1023/A:1008815005736
   PubMed Web of Science ®Google Scholar
• Moriarty DG, Zack MM, Kobau R. The centers for disease control and prevention’s healthy days measures – population tracking of perceived physical and mental health over time. Health Qual Life Outcomes. 2003;1(1):37. doi:10.1186/1477-7525-1-37
   PubMedGoogle Scholar
• The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551–558. doi:10.1017/S0033291798006667
   PubMed Web of Science ®Google Scholar
• Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727. doi:10.1007/s11136-012-0322-4
   PubMed Web of Science ®Google Scholar
• Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54. doi:10.1186/1477-7525-1-54
   PubMedGoogle Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292. doi:10.1016/S0167-6296(01)00130-8
   PubMed Web of Science ®Google Scholar
• Thavorncharoensap M. Measurement of utility. J Med Assoc Thai. 2014;97(Suppl 5):S43–49.
   PubMedGoogle Scholar
• Cesnales NI, Thyer BA. Health-related quality of life measures. In: Michalos AC, editor. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht: Springer Netherlands; 2014:2809–2814.
   Google Scholar
• Janković S, Perić J, Maksimović N, et al. Quality of life in patients with alopecia areata: a hospital-based cross-sectional study. J Eur Acad Dermatol Venereol. 2016;30(5):840–846. doi:10.1111/jdv.13520
   Web of Science ®Google Scholar
• Apolone G, De Carli G, Brunetti M, Garattini S. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics. 2001;19(2):187–195. doi:10.2165/00019053-200119020-00005
   Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–713. doi:10.1111/1523-1747.ep12365600
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105–110. doi:10.1177/120347540100500202
   PubMed Web of Science ®Google Scholar
• Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: skindex-17. J Invest Dermatol. 2006;126(6):1244–1250. doi:10.1038/sj.jid.5700212
   Web of Science ®Google Scholar
• Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales--a measure of the impact of skin diseases. Br J Dermatol. 1997;136(2):202–206.
   PubMed Web of Science ®Google Scholar
• Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127(12):2726–2739. doi:10.1038/sj.jid.5701142
   PubMed Web of Science ®Google Scholar
• Lewis VJ, Finlay AY. A critical review of quality-of-life scales for psoriasis. Dermatol Clin. 2005;23(4):707–716. doi:10.1016/j.det.2005.05.016
   Web of Science ®Google Scholar
• Barber B, Kaufman K, Kozloff R, Girman C, Guess H. A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatol Treat. 1998;9(3):181–186. doi:10.3109/09546639809160551
   Web of Science ®Google Scholar
• The Kingsley Alopecia Profile (KAP). Available from: https://worldtrichologysociety.org/society/knowledgebase/the-kingsley-alopecia-profile-kap/. Accessed May 24, 2021.
   Google Scholar
• Kingsley D. The Development and Validation of a Quality of Life Measure for the Impact of Androgen-Dependent Alopecia. Portsmouth: Portsmouth University; 1999.
   Google Scholar
• Dolte KS, Girman CJ, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol. 2000;25(8):637–642. doi:10.1046/j.1365-2230.2000.00726.x
   Web of Science ®Google Scholar
• Shimizu GKM, Wedy GF, Schaefer LV, Ramos PM, Miot HA. Translation into Portuguese language (Brazil), transcultural adaptation and validation of the quality of life questionnaire in female pattern hair loss (WAA-QoL-BP). An Bras Dermatol. 2018;93(5):701–706. doi:10.1590/abd1806-4841.20187452
   Web of Science ®Google Scholar
• Fischer TW, Schmidt S, Strauss B, Elsner P. [Hairdex: a tool for evaluation of disease-specific quality of life in patients with hair diseases]. Hautarzt. 2001;52(3):219–227. German. doi:10.1007/s001050051293
   Web of Science ®Google Scholar
• Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670–675. doi:10.1001/jamadermatol.2018.0454
   PubMed Web of Science ®Google Scholar
• Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724–728. doi:10.1001/jamadermatol.2018.5071
   Web of Science ®Google Scholar
• Sawant N, Chikhalkar S, Mehta V, Ravi M, Madke B, Khopkar U. Androgenetic Alopecia: quality-of-life and associated lifestyle patterns. Int J Trichology. 2010;2(2):81–85. doi:10.4103/0974-7753.77510
   PubMedGoogle Scholar
• Gonul M, Cemil BC, Ayvaz HH, Cankurtaran E, Ergin C, Gurel MS. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata. An Bras Dermatol. 2018;93(5):651–658. doi:10.1590/abd1806-4841.20186131
   PubMed Web of Science ®Google Scholar
• Harness J, Mamolo C, Olsen E, Price V. The women’s hair growth questionnaire: development and validation of a patient-reported measure for treatment efficacy in androgenetic alopecia. J Am Acad Dermatol. 2009;60(3):AB100.
   Web of Science ®Google Scholar
• Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531–536. doi:10.1684/ejd.2012.1752
   Web of Science ®Google Scholar
• Han SH, Byun JW, Lee WS, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012;24(3):311–318. doi:10.5021/ad.2012.24.3.311
   PubMed Web of Science ®Google Scholar
• Guerra-Tapia A, Buendía-Eisman A, Ferrando J. Validation of a cross-cultural adaptation of the hair specific Skindex-29 scale to Spanish. Actas Dermosifiliogr. 2018;109(5):424–431. doi:10.1016/j.ad.2018.02.007
   Web of Science ®Google Scholar
• Guerra-Tapia A, Buendía-Eisman A, Ferrando Barbera J. Final phase in the validation of the cross-cultural adaptation of the hair-specific Skindex-29 questionnaire into Spanish: sensitivity to change and correlation with the 12-item short-form health survey. Actas Dermosifiliogr. 2019;110(10):819–829. doi:10.1016/j.ad.2019.06.003
   Web of Science ®Google Scholar
• Gupta S, Goyal I, Mahendra A. Quality of life assessment in patients with androgenetic alopecia. Int J Trichology. 2019;11(4):147–152. doi:10.4103/ijt.ijt_6_19
   PubMedGoogle Scholar
• Romanova Y, Romanov DV, Brazhnikov A, Voronova EI, Lvov AN, Potekaev NN. Perspective targets for secondary prevention of quality of life decrease and psychosomatic disorders in alopecia: results of an observational study. Profilakticheskaya Meditsina. 2019;22(5):104–111. doi:10.17116/profmed201922051104
   Google Scholar
• Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc. 2013;16(1):S51–52. doi:10.1038/jidsymp.2013.19
   Google Scholar
• Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19(1):S41–s46. doi:10.1016/j.jisp.2017.10.009
   Google Scholar
• Fabbrocini G, Panariello L, De Vita V, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276–281. doi:10.1111/j.1468-3083.2012.04629.x
   PubMed Web of Science ®Google Scholar
• Dlova NC, Fabbrocini G, Lauro C, Spano M, Tosti A, Hift RH. Quality of life in South African Black women with alopecia: a pilot study. Int J Dermatol. 2016;55(8):875–881. doi:10.1111/ijd.13042
   Web of Science ®Google Scholar
• SKINDEX-16 for Alopecia Areata (SKINDEX-16 for AA). Available from: https://eprovide.mapi-trust.org/instruments/skindex-16-for-alopecia-areata. Accessed May 24, 2021.
   Google Scholar
• Aldhouse NVJ, Kitchen H, Knight S, et al. “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76. doi:10.1186/s41687-020-00240-7
   PubMedGoogle Scholar
• Finlay AY. Quality of life in dermatology: after 125 years, time for more rigorous reporting. Br J Dermatol. 2014;170(1):4–6. doi:10.1111/bjd.12737
   Web of Science ®Google Scholar
• McCombs K, Chen SC. Patient preference quality of life measures in dermatology. Dermatol Ther. 2007;20(2):102–109. doi:10.1111/j.1529-8019.2007.00118.x
   Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services; 2009.
   Google Scholar
• Arnould B, Pierson RF, Chan E, Savre I, Acquadro C. A review of clinical outcome assessment labeling in Europe and in the United States (2013–2016). Value Health. 2017;20(9):A742. doi:10.1016/j.jval.2017.08.2051
   Web of Science ®Google Scholar
• Salek S, Roberts A, Finlay AY. The practical reality of using a patient-reported outcome measure in a routine dermatology clinic. Dermatology. 2007;215(4):315–319. doi:10.1159/000107625
   Web of Science ®Google Scholar
• Reid EE, Haley AC, Borovicka JH, West DP, Wickless H. Quality of life correlates more closely with patient-rated versus physician-rated hair loss severity in women with non-scarring alopecia. J Investigat Dermatol. 2010;130:S45.
   Web of Science ®Google Scholar
• Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;66(3):e97–102. doi:10.1016/j.jaad.2010.11.042
   PubMed Web of Science ®Google Scholar
• Finlay AY, Salek MS, Abeni D, et al. Why quality of life measurement is important in dermatology clinical practice: an expert-based opinion statement by the EADV task force on quality of life. J Eur Acad Dermatol Venereol. 2017;31(3):424–431. doi:10.1111/jdv.13985
   PubMed Web of Science ®Google Scholar
• Leppink EW, Redden SA, Grant JE. A double-blind, placebo-controlled study of inositol in trichotillomania. Int Clin Psychopharmacol. 2017;32(2):107–114. doi:10.1097/YIC.0000000000000156
   Web of Science ®Google Scholar
• Chen Q, Tao Y, Wang L, Zhang J, Sun B, Yang X. A randomized controlled clinical study of acupuncture therapy for Seborrheic alopecia in young and middle ages: study protocol clinical trial (SPIRIT compliant). Medicine. 2020;99(17):e19842. doi:10.1097/MD.0000000000019842
   Web of Science ®Google Scholar
• Katoulis AC, Liakou AI, Koumaki D, et al. A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia. Dermatol Ther. 2020;33(4):e13734. doi:10.1111/dth.13734
   Web of Science ®Google Scholar
• Tsai TF, Choi GS, Kim BJ, et al. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol. 2018;45(7):799–804. doi:10.1111/1346-8138.14329
   Web of Science ®Google Scholar
• Lai VWY, Chen G, Gin D, Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019;81(3):694–701. doi:10.1016/j.jaad.2019.04.053
   PubMed Web of Science ®Google Scholar
• Lai VWY, Chen G, Sinclair R. Impact of cyclosporin treatment on health-related quality of life of patients with alopecia areata. J Dermatolog Treat. 2021;32(2):250–257. doi:10.1080/09546634.2019.1654068
   PubMed Web of Science ®Google Scholar
• da Silveira SP, Moita SRU, da Silva SV, Rodrigues M, da Silva DFT, Pavani C. The role of photobiomodulation when associated with microneedling in female pattern hair loss: a randomized, double blind, parallel group, three arm, clinical study protocol. Medicine. 2019;98(12):e14938. doi:10.1097/MD.0000000000014938
   Web of Science ®Google Scholar
• Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–253. doi:10.1016/j.jaad.2019.08.060
   PubMed Web of Science ®Google Scholar
• Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132. doi:10.1186/1745-6215-13-132
   PubMed Web of Science ®Google Scholar
• Kanokrungsee S, Anuntrangsee T, Tankunakorn J, Srisuwanwattana P, Suchonwanit P, Chanprapaph K. Rituximab therapy for treatment of pemphigus in Southeast Asians. Drug Des Devel Ther. 2021;15:1677–1690. doi:10.2147/DDDT.S306046
   Web of Science ®Google Scholar
• Rattanakaemakorn P, Pinyowiwat P, Iamsumang W, Chanprapaph K, Suchonwanit P. Incidence and risk factors of hepatic fibrosis in psoriatic patients receiving methotrexate with concomitant acitretin therapy and methotrexate monotherapy. Drug Des Devel Ther. 2021;15:2299–2307. doi:10.2147/DDDT.S304168
   Web of Science ®Google Scholar
• Chanprapaph K, Fakprapai W, Limtong P, Suchonwanit P. Nailfold capillaroscopy with USB digital microscopy in connective tissue diseases: a comparative study of 245 patients and healthy controls. Front Med. 2021;8:683900. doi:10.3389/fmed.2021.683900
   Web of Science ®Google Scholar
• Rattanakaemakorn P, Triyangkulsri K, Iamsumang W, Suchonwanit P. 308-nm excimer lamp vs. combination of 308-nm excimer lamp and 10% liquor carbonis detergens in patients with scalp psoriasis: a randomized, single-blinded, controlled trial. Front Med. 2021;8:677948. doi:10.3389/fmed.2021.677948
   Web of Science ®Google Scholar
• Prinsen CAC, Spuls PI, Kottner J, et al. Navigating the landscape of core outcome set development in dermatology. J Am Acad Dermatol. 2019;81(1):297–305. doi:10.1016/j.jaad.2019.03.009
   Web of Science ®Google Scholar
• Core outcome set for hair loss/non-scarring alopecia. Available from: https://www.cometinitiative.org/Studies/Details/759. Accessed May 24, 2021.
   Google Scholar
• Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol. 2021;84(6):1594–1601. doi:10.1016/j.jaad.2020.09.028
   PubMed Web of Science ®Google Scholar